Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

被引：0
|
作者：
Spelman, Lynda [1 ]
Warren, Richard B. [2 ]
Sofen, Howard [3 ]
Imafuku, Shinichi [4 ]
Blauvelt, Andrew [5 ]
Toms, Jessica [6 ]
Buck, Alex [7 ]
Banerjee, Subhashis [6 ]
Menter, Alan [8 ]
Szepietowski, Jacek C. [9 ]
机构：
[1] Verac Clin Res, Brisbane, Qld, Australia
[2] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England
[3] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[4] Fukuoka Univ Hosp, Fukuoka, Japan
[5] Oregon Med Res Ctr, Portland, OR USA
[6] Bristol Myers Squibb, New York, NY USA
[7] Cytel Inc, Bristol Myers Squibb, Dallas, TX USA
[8] Baylor Univ, Med Ctr, Waco, TX 76798 USA
[9] Wroclaw Med Univ, Wroclaw, Poland
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：28 / 28
页数：1
相关论文
共 50 条
  • [21] Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
    Strober, Bruce
    Blauvelt, Andrew
    Warren, Richard B.
    Papp, Kim A.
    Armstrong, April W.
    Gordon, Kenneth B.
    Morita, Akimichi
    Alexis, Andrew F.
    Lebwohl, Mark
    Foley, Peter
    Kisa, Renata M.
    Colston, Elizabeth
    Wang, Tao
    Banerjee, Subhashis
    Thaci, Diamant
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (08) : 1543 - 1554
  • [22] Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies
    Baraliakos, Xenofon
    Deodhar, Atul
    van der Heijde, Desiree
    van den Bosch, Filip
    Magrey, Marina
    Maksymowych, Walter P.
    Tomita, Tetsuya
    Xu, Huji
    Massow, Ute
    Vaux, Tom
    Prajapati, Chetan
    Manente, Myriam
    Marten, Alexander
    Gensler, Lianne S.
    RHEUMATOLOGY, 2025,
  • [23] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 2
    Gooderham, M.
    Papp, K.
    Blauvelt, A.
    Thaci, D.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 62
  • [24] Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1
    Crowley, Jeffrey
    Korman, Neil J.
    Spelman, Lynda
    Igarashi, Atsuyuki
    Gupta, Aditya K.
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Eads, Kimberly M.
    Guenthner, Scott T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB162 - AB162
  • [25] Deucravacitinib in moderate to severe plaque psoriasis: Correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2
    Rubel, Diana
    Armstrong, April W.
    Papp, Kim
    Zhuo, Joe
    Becker, Brandon
    Zhong, Yichen
    Beaumont, Jennifer
    DeRosa, Michael
    Kisa, Renata M.
    Banerjee, Subhashis
    Strober, Bruce
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 71 - 72
  • [26] Adalimumab long-term safety/efficacy results for pediatric patients with chronic plaque psoriasis from a phase 3, randomized study
    Papp, Kim
    Marcoux, Danielle
    Landells, Ian
    Weibel, Lisa
    Ghislain, Pierre-Dominique
    Unnebrink, Kristina
    Williams, David
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB209 - AB209
  • [27] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1
    Tyring, S.
    Spelman, L.
    Igarashi, A.
    Ohtsuki, M.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Guenthner, S.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 61
  • [28] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
    Gooderham, Melinda
    Spelman, Lynda
    Imafuku, Shinichi
    Romanelli, Marco
    Merola, Joseph F.
    Armstrong, April W.
    Colston, Elizabeth
    Banerjee, Subhashis
    Scharnitz, Thomas
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB35 - AB35
  • [29] Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and PSO-2 trials
    Augustin, Matthias
    Strober, Bruce
    Armstrong, April W.
    Beaumont, Jennifer
    Pham, Tan P.
    Hudgens, Stacie
    Zhuo, Joe
    Becker, Brandon
    Banerjee, Subhashis
    Kisa, Renata M.
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB156 - AB156
  • [30] Safety and tolerability of tildrakizumab in patients with chronic plaque psoriasis: Results from long-term extensions of 2 phase 3 studies
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Papp, K. A.
    Kimball, A.
    Sinclair, R.
    Tyring, S.
    Cichanowitz, N.
    Li, Q.
    Green, S.
    La Rosa, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 110 - 111
12345